Cell Death and Disease (Jul 2022)

CHST15 gene germline mutation is associated with the development of familial myeloproliferative neoplasms and higher transformation risk

  • Yi Chen,
  • Yang Zhang,
  • Zhihua Wang,
  • Yewei Wang,
  • Yujiao Luo,
  • Nannan Sun,
  • Shasha Zheng,
  • Wenzhe Yan,
  • Xiang Xiao,
  • Sufang Liu,
  • Ji Li,
  • Hongling Peng,
  • Yunxiao Xu,
  • Guoyu Hu,
  • Zhao Cheng,
  • Guangsen Zhang

DOI
https://doi.org/10.1038/s41419-022-05035-w
Journal volume & issue
Vol. 13, no. 7
pp. 1 – 11

Abstract

Read online

Abstract Herein, we describe the clinical and hematological features of three genetically related families predisposed to myeloproliferative neoplasms (MPNs). Using whole-exome sequencing, we identified a c.1367delG mutation(p.Arg456fs) in CHST15 (NM_001270764), a gene encoding a type II transmembraneglycoproteinthat acts as a sulfotransferase and participates in the biosynthesis of chondroitin sulfate E, in germline and somatic cells in familial MPN. CHST15defects caused an increased JAK2V617F allele burden and upregulated p-Stat3 activity,leading to an increase in the proliferative and prodifferentiation potential of transgenic HEL cells. We demonstrated that mutant CHST15 is able to coimmmunoprecipitate the JAK2 protein,suggesting the presence of a CHST15-JAK2-Stat3 signaling axis in familial MPN. Gene expression profiling showed that the FREM1, IFI27 and C4B_2 genes are overexpressed in familial MPN, suggesting the activation of an “inflammatory response-extracellular matrix-immune regulation” signaling network in the CHST15 mutation background.We thus concluded that CHST15 is a novel gene that predisposes to familial MPN and increases the probability of disease development or transformation.